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ABSTRACT
Aim To estimate the prevalence of age-related
maculopathy (ARM) and age-related macular
degeneration (AMD) in the Spanish population aged
$65 years.
Methods Individuals were selected by random stratified
sampling of census data from eight Spanish health
districts encompassing a wide geographic area.
Participants underwent an ophthalmologic evaluation
including fundus imaging, and ARM and AMD were
defined according to the International ARM
Epidemiological Study Group classification. The
age- and gender-adjusted prevalences and CIs for ARM
and neovascular and atrophic forms of AMD were
calculated.
Results Of the 3028 individuals invited to participate,
2132 attended the ophthalmologic evaluation (840 men
(70.9% response) and 1292 women (69.7% response);
978 aged 65e74 years (77.6% response), 1154 aged
$75 years (65.3% response)). The overall prevalence of
ARM and AMD was 10.3% (95% CI 8.7% to 11.8%) and
3.4% (95% CI 2.5% to 4.3%), respectively. AMD
increased from 1.3% in individuals aged 65e74 years to
8.5% in those aged $80 years. Neovascular and
atrophic AMD accounted for 1.9% and 1.5% of
individuals, respectively.
Conclusions The prevalence of AMD in this large,
population-based Spanish sample was similar to that
observed in other large-scale population-based studies.
However, the prevalence of ARM was lower than found
in similar studies.
INTRODUCTION
Age-related maculopathy (ARM) is essentially
characterised by the presence of drusen.1 The term
encompasses a wide range of retinal disorders and
visual impairment. Progression of maculopathy
eventually leads to age-related macular degenera-
tion (AMD), which is also one of the principal
causes of reduced vision and legal blindness among
the elderly in developed countries.2 Even when
AMD does not lead to blindness, there is a strong
negative impact on independence and quality of
life.3
Two main forms of AMD have been identified4:
geographic atrophy associated with extensive loss of
the choriocapillaris and overlying retinal pigment
epithelium and neovascular AMDdthe more
aggressive formdin which blood and serum leakage
from newly formed blood vessels in the macular
region of the retina causes irreversible damage and
progressive vision loss. Although the neovascular
form is generally less common,5 it is responsible for
a larger proportion of severe loss of visual acuity
related to AMD.6 Tobacco smoking is the main
modifiable risk factor for the development of
AMD.7 In addition to age, the disease has been
associated with family history, exposure to
sunlight, light-coloured iris, dietary factors8 and,
more recently, certain genetic factors.9 A link
between cardiovascular disease and AMD has also
been reported,10 possibly as a result of inflammatory
processes common to the two diseases.11
The prevalence of ARM and AMD in Spain is of
particular interest since only limited data are
currently available on southern European countries.
To date, however, although some studies have
reported prevalences for specific groups within the
Spanish population,12 13 none has addressed the
overall prevalence of macular degeneration. In view
of the paucity of population-based epidemiological
data on ARM in Spain and the expected increase in
absolute prevalence of ARM with increasing age of
the population,14 we undertook the present study.
The aim was to collect epidemiological data
on prevalence among individuals aged 65 years
or more, according to rigorous internationally
standardised methodology.15
METHODS
This was a population-based, cross-sectional,
epidemiological study of ARM and AMD in the
Spanish population. The protocol, which was
approved by the ethics committee of Hospital La
Paz (Madrid, Spain), was in compliance with
guidelines on Good Clinical Practice and the
Declaration of Helsinki (2002). The sample was
obtained by random stratified sampling. The strata
corresponded to individual health districts, which
are existing geographic regions of Spain in which all
members of the resident population are assigned to
a specialist care unit. The sample comprised eight
health districts in six Spanish provinces chosen to
ensure adequate geographic spread: Madrid (central
Spain, 311 participants), Oviedo (northwest Spain,
318 participants), Barcelona and Hospitalet de
Llobregat (northeast Spain, 421 participants),
Valencia (eastern Spain, 305 participants), Seville
and Dos Hermanas (southern Spain, 474 partici-
pants) and Santa Cruz de Tenerife (Canary Islands,
303 participants). In each health district, sample
elements were selected by simple random sampling
of all individuals aged at least 65 years who were
resident in that district according to current census
data. Thus, the sampling process ensured that all
contacts were directed towards individuals who
were resident in each district and included indi-
viduals with public healthcare coverage and those
with additional private healthcare plans. The
sample was divided into the following main age
groups: 65e74 years and $75 years. The weighting
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assigned to health district reflected the percentage of individuals
in each age group registered in that district. The relative
weighting of the different age groups did not, however, reflect
the age profile (see below).
Sample size and statistical analysis
To ensure that a random sample was obtained and to increase
the response rate, the fieldwork was organised in various stages.
First, initial telephone contact was made to explain the aims of
the study and invite individuals to participate. Each participant
was then sent a letter containing detailed information about the
study and confirming that it would take place at their corre-
sponding referral hospital. The letter was accompanied by
a leaflet on AMD. Afterwards, each participant was contacted
again, either by telephone or by personal visit according to
individual needs, to confirm the date and time of the hospital
appointment. The use of health districts as sampling units in the
first step favours participation since all participants were seen in
the corresponding referral hospital for their health area. All
selected individuals who had agreed to participate but who did
not attend their appointment were offered another appointment
in an effort to increase participation. Furthermore, attendance
was encouraged by providing transport to and from the hospital
for any individual with mobility restrictions or who simply
requested this service.
At first visit, the nature of the study was explained again in
detail and signed informed consent was obtained. Sociodemo-
graphic and clinical data of interest were then collected. These
included information on chronic diseases, medications,
ophthalmologic comorbidities (diabetic retinopathy, glaucoma,
prior eye surgery, occlusive vascular diseases and congenital
disorders), family history of AMD and habits related to
the pathology, such as tobacco use. In addition, participants
were administered a specific questionnaire to assess health
status, Katz Index of Independence in Activities of Daily Living
and Hospital Anxiety and Depression (HAD) scale. At the
end of the visit, an appointment was made with the eye
specialist.
Ophthalmologic examination
All individuals who agreed to see the eye specialist underwent an
eye examination consisting of measurement of visual acuity
(Snellen scale), anterior segment biomicroscopy with applana-
tion tonometry, fundus observation with 90-dioptre non-contact
lens for macular area and indirect binocular ophthalmoscopy
and colour fundus retinography. The protocols and equipment
used were the same for all participating centres.
Colour fundus retinography was centred on the macular area
and carried out under pharmacological mydriasis. In cases of
dense lens opacities or the absence of vitreous transparency, the
best images obtained were registered. Fundus images were
obtained with a non-mydriatic TCR-NW6S camera (Topcon
Inc., Japan) and IMAGEnet i-base (Topcon Inc., Japan) digital
imaging software or a TRC-50IX camera with a Sony 3CCD
(Sony Inc., Japan) colour video recorder connected to an
IMAGEnet 2000 imaging system (version 2.59; Topcon Inc.,
Japan). Fluorescein angiography was performed in participants
for whom diagnosis was uncertain.
Maculopathy grading
The severity of maculopathy was graded based on the criteria of
the International ARM Epidemiological Study Group15 and
classified into five stages, as defined elsewhere.16 17 If an indi-
vidual had eyes with different ARM grades, the worst grade of
severity was recorded. AMD type was classified as atrophic or
neovascular using the standard definition of the International
ARM Epidemiological Study Group,15 and participants were
classified as having bilateral disease or unilateral disease.
The initial classification and grading were recorded in each of
the participating centres. All images were then re-evaluated by
an investigator from another participating centre, who was
unaware of the initial classification and grading. Discrepancies
were reviewed by a panel of four experts from among the study
coordinators.
Sample size and statistical analysis
The sample size was calculated in order to estimate the preva-
lence of AMD with a sampling error of 61% for the overall
population, 61% for the population aged 65e74 years and
61.5% for the population aged$75 years with a 95% confidence
level. To guarantee the required reliability, the sample size
corresponded to the final valid sample. Although the reliability
required for the $75 age group is lower in absolute terms, the
actual reliability is greater in relative terms (coefficient of vari-
ation) as a result of the greater expected prevalence (reducing
sampling error/expected prevalence). For the stated aim of















Light coloured 510 (23.9%)
Brown 1622 (76.1%)
Systemic comorbidities*
Arthritis or rheumatism 1178 (55.5%)
Hypertension 911 (42.7%)
Depression or anxiety 506 (23.7%)
Ischaemic heart disease 446 (20.9%)
Headache 388 (18.2%)
Diabetes 386 (18.1%)
Asthma or chronic bronchitis 269 (12.6%)
*Occurring in >10% of the study population.
Table 2 Ophthalmologic comorbidity associated with age-related




Diabetic retinopathy 3.3 3.4 2.8 2.8
Glaucoma 6.5 6.3 8.3 5.6
Congenital degeneration of the retina 0.1 0.1 0.5 e
Ocular tumour 0.2 0.2 0.5 e
Cataracts 36.1 34.9 42.3 46.5
Vascular retinopathies 1.2 1.1 1.4 4.2
Diabetic macular oedema 0.5 0.4 0.1 2.8
Previous cataract surgery/other ocular
surgery
29.5 27.4 38.9 54.9
*Data are shown as percentages.
2 of 6 Br J Ophthalmol (2010). doi:10.1136/bjo.2010.187773
Clinical science
 group.bmj.com on January 14, 2011 - Published by bjo.bmj.comDownloaded from 
determining prevalences for the 65e74 age group and the $75
age group, the sample size of the valid populationdexcluding
non-responders and with non-proportional assignment by age
groupdwas 950 interviews for the 65e74 age group and 1100
interviews for the $75 age group.
Since the allocation by age group was not proportional,
standard weighting factors applied in stratified sampling (by
gender and age group, according to the structure of the Spanish
population aged $65 years) were used in estimations of preva-
lence. Estimates of the prevalence of early ARM and AMD were
accompanied by 95% CIs after taking into account the design
effect (ratio of the variance with random stratified sampling to
that with simple random sampling). Given the estimation
procedure and selection method used in the process of sampling
according to health district, which guarantees that representa-
tive samples are obtained, there was no requirement for analysis
of homogeneity upon combining samples from each district. All
data were analysed at a single site using SPSS version 13.0 (SPSS




The characteristics of the study population are shown in table 1.
In total, 3028 individuals were contacted and the final valid
sample comprised 2132 participants (response rate, 70.4%). The
response rate was very similar in men (70.9%) and women
(69.7%) but was higher in participants aged between 65 and
74 years (77.6%) than in those aged $75 years (65.3%). Non-
responders included those who were initially selected but with
whom it was impossible to establish contact due to repeated
absence, cancelled home visits, etc. (2.7%), those who were
successfully contacted but who declined to participate either due
to express refusal or inability to attend the centre (6.6%) and
those who agreed to participate but did not attend the eye
examination on the stipulated day (20.3%). In 65 participants
who did attend the eye examination (3.0% of the final valid
sample), it was not possible to classify the image in at least one
eye. Cataracts were the most common ophthalmologic comor-
bidity, reported in 36% of the overall sample (table 2). In addition,
30% had undergone prior ocular surgery for cataracts or other
conditions. There was no association between either smoking or
eye colour and the presence of ARM or AMD (data not shown).
Prevalence of ARM and AMD
Table 3 shows the prevalence of each grade of ARM and AMD by
gender and age. The overall prevalence of ARM (grades 1e3) in
our study sample was 10.3% (95% CI 8.7% to 11.8%), with
a greater prevalence in women (11.6%; 95% CI 9.5% to 13.7%)
than men (8.8%; 95% CI 6.5% to 11.1%), although this differ-
ence was not statistically significant (age-adjusted prevalence
ratio was 1.26 (95% CI 0.93 to 1.70)). The overall prevalence of
Table 3 Prevalence of age-related maculopathy (ARM) and age-related macular degeneration (AMD) by gender and age*
Without ARM/AMD ARM AMD
Grade 0 (n[1779) Grade 1 (n[165) Grade 2 (n[44) Grade 3 (n[8) Grade 4 (n[71)
Overall (n¼2132) 86.3 (84.5 to 87.9) 7.9 (6.5 to 9.3) 2.0 (1.3 to 2.7) 0.4 (0.1 to 0.7) 3.4 (2.5 to 4.3)
Gender
Men (n¼840) 87.6 (84.9 to 90.3) 7.4 (5.3 to 9.5) 1.1 (1.3 to 3.9) 0.3 (0.0 to 0.7) 3.6 (2.1 to 5.1)
Women (n¼1292) 85.1 (82.8 to 87.4) 8.7 (6.9 to 10.5) 2.5 (1.5 to 3.5) 0.4 (0.0 to 0.8) 3.3 (2.1 to 4.5)
Age group
65e69 years (n¼472) 94.0 (91.5 to 96.5) 5.1 (2.7 to 7.5) 0.1 (0.0 to 0.5) 0.1 (0.0 to 0.7) 0.7 (0.0 to 1.6)
70e74 years (n¼506) 88.6 (85.3 to 91.9) 7.1 (4.5 to 9.8) 2.4 (0.9 to 4.0) 0.1 (0.0 to 0.4) 1.8 (0.4 to 3.2)
75e79 years (n¼605) 86.7 (83.5 to 89.9) 7.9 (5.4 to 10.4) 2.6 (1.1 to 4.1) 0.4 (0.0 to 1.0) 2.4 (0.9 to 3.8)
80 years and older (n¼549) 76.0 (71.8 to 80.2) 11.7 (8.5 to 14.9) 3.1 (1.4 to 4.8) 0.7 (0.0 to 1.5) 8.5 (5.7 to 11.3)
65e74 years (n¼978) 91.2 (89.1 to 93.3) 6.1 (4.4 to 8.0) 1.3 (0.5 to 2.1) 0.1 (0.0 to 0.3) 1.3 (0.5 to 2.2)
75 years and older (n¼1154) 80.9 (78.2 to 83.6) 9.9 (7.9 to 11.9) 2.9 (1.7 to 4.1) 0.6 (0.1 to 1.1) 5.7 (4.1 to 7.3)
Grade 0, absence of any signs of grades 1e3.
Grade 1, soft distinct drusen ($63 mm) only or pigmentary abnormalities only (no soft drusen).
Grade 2, soft indistinct drusen ($125 mm) or reticular drusen only or soft indistinct drusen ($63 mm) with pigmentary abnormalities.
Grade 3, soft indistinct drusen ($125 mm) or reticular drusen only with pigmentary abnormalities.
Grade 4, atrophic or neovascular AMD. In 65 cases, it was not possible to classify the image obtained for at least one eye.
*Data are shown as percentages and 95% CIs.
Table 4 Prevalence of age-related macular degeneration (AMD) by gender and age*
AMD
Neovascular (n[38) Atrophic (n[33) Unilateral (n[48) Bilateral (n[23) Total (n[71)
Overall (n¼2132) 1.9 (1.1 to 2.6) 1.5 (0.9 to 2.1) 2.3 (1.5 to 3.1) 1.1 (0.6 to 1.6) 3.4 (2.5 to 4.3)
Gender
Men (n¼840) 2.5 (1.2 to 3.7) 1.1 (0.3 to 1.9) 2.6 (1.3 to 3.9) 1.0 (0.2 to 1.8) 3.6 (2.1 to 5.1)
Women (n¼1292) 1.4 (0.6 to 2.2) 1.9 (1.0 to 2.8) 2.1 (1.2 to 3.0) 1.2 (0.5 to 1.9) 3.3 (2.1 to 4.5)
Age group
65e69 years (n¼472) 0.5 (0.0 to 1.3) 0.2 (0.0 to 0.7) 0.5 (0.0 to 1.3) 0.2 (0.0 to 0.7) 0.7 (0.0 to 1.6)
70e74 years (n¼506) 1.4 (0.2 to 2.6) 0.4 (0.0 to 1.1) 1.5 (0.2 to 2.8) 0.3 (0.0 to 0.9) 1.8 (0.4 to 3.2)
75e79 years (n¼605) 0.5 (0.0 to 1.2) 1.9 (0.6 to 3.2) 1.8 (0.6 to 3.1) 0.6 (0.0 to 1.3) 2.4 (0.9 to 3.8)
80 years and older (n¼549) 4.4 (2.4 to 6.4) 4.1 (2.1 to 6.1) 5.4 (3.2 to 7.6) 3.1 (1.4 to 4.8) 8.5 (5.7 to 11.3)
65e74 years (n¼978) 1.0 (0.3 to 1.7) 0.3 (0.0 to 0.7) 1.0 (0.3 to 1.7) 0.3 (0.0 to 0.7) 1.3 (0.5 to 2.2)
75 years and older (n¼1154) 2.7 (1.6 to 3.8) 3.0 (1.8 to 4.2) 3.7 (2.4 to 5.0) 2.0 (1.0 to 3.0) 5.7 (4.1 to 7.3)
*Data are shown as percentages and 95% CIs.
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AMD showed little difference between men and women (age-
adjusted prevalence ratio was 0.78 (95% CI 0.48 to 1.27)). The
prevalence of both ARM and AMD increased with age, and in
both cases there was a marked increase in the population aged at
least 80 years.
Neovascular AMD accounted for 54% of cases compared with
46% with the atrophic form (table 4). The neovascular form was
more prevalent in men than women (2.5% vs 1.4%). Compar-
ison of the relative proportion of participants with the neovas-
cular and the atrophic form by broad age group revealed
a reduction in neovascular AMD (from 76% in the 65e74 years
age group to 47% in individuals $75 years age group), although
the trend was less clear when comparing 5-year age intervals
(table 4). The prevalence of bilateral disease remained below 1%
up to 79 years, but increased to 3.1% (95% CI 1.4% to 4.8%) in
the $80 years age group. This difference between participants
#79 years and those $80 years was significant (p<0.001).
Visual acuity
Table 5 shows the proportion of participants with impaired visual
acuity associated with ARM (grades 1e3) or AMD (grade 4).
Approximately half the participants (51%) with ARM had visual
acuity >20/40 compared with only 16% of those with AMD.
Among the participants with AMD, 47% had very severe deteri-
oration in visual acuity (defined as <20/400). The proportion of
participants with ARM or AMD and at least a mild reduction in
visual acuity (<20/40) was slightly lower in those with cataracts
(62.7%) than in those who had previously undergone cataract
surgery (67.8%).
DISCUSSION
The overall prevalence of ARM in our sample of Spanish indi-
viduals aged 65 years or older was 10.3%, while the prevalence of
AMDwas 3.4%. According to official census data for the Spanish
population, there are approximately 7.5 million individuals aged
65 years or more (Municipal Register of Inhabitants, 2007;
Spanish National Institute of Statistics; http://www.ine.es/).
The results of our study therefore suggest that, in Spain,
approximately 255 000 individuals have AMD, while 773 000
individuals have ARM and so are at risk of progressing to
AMD.18 Given the substantial impact of the associated vision
loss on quality of life,3 this represents a heavy societal burden.19
Although formal modelling would be required to provide an
accurate prediction of the trends in prevalence of these condi-
tions, taking into account the influx of younger immigrants, the
availability of treatments20 and the possible use of antioxidant
therapy to slow early disease progression,21 it seems likely that
this burden will only increase as the population ages.
The prevalence of AMD observed in this study was similar to
that observed in other studies with comparable age ranges (table
6). Interestingly, the prevalence for individuals $65 years in our
study was similar to the overall prevalence for that age group in
the European Eye Study (EUREYE), but higher than the preva-
lence of 1.34% observed when considering only the participants
included at the Spanish centre. Although it may be tempting to
speculate that this difference reflects regional differences in the
prevalence of AMD within Spain, care must be taken not to over
interpret the findings of the two studies. Our study included
a substantially larger number of Spanish participants over a much
wider geographic area as it was designed to provide a reliable
estimate of the prevalence throughout Spain. However, it was not
designed to assess regional differences and further studies
involving careful control of the multiple genetic, lifestyle-related
and climatic factors that could be proposed to explain putative
differences in prevalence would be required in order to address this
question.
Our study benefitted from a number of measures to increase
participation, including initial telephone contact and subsequent
follow-up, and this may account for the higher response rate
than in studies where such measures were not possible.12
Nevertheless, despite the high response rate and the strictly
random selection of participants based on census data,
Table 5 Visual acuity impairment associated with age-related maculopathy (ARM) and age-related macular degeneration (AMD)*





>20/40 57.3 59.6 50.6 15.5 37.3 32.2
Mild (20/40e20/80) 22.8 22.6 29.8 7.0 29.8 23.6
Moderate (20/80e20/200) 9.0 8.9 10.7 8.5 8.7 10.7
Severe (20/200e20/400) 5.3 4.8 4.2 22.5 9.0 10.6
Very severe (<20/400) 5.6 4.1 4.7 46.5 15.2 22.9
*Data are shown as percentages.
Table 6 Comparative prevalences of age-related macular degeneration (AMD) in different population-based studies*
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individuals who perceived themselves as having poorer vision
may have been more likely to attend, thus introducing a poten-
tial source of bias. We also note that the study period coincided
with a certain degree of expectation about new treatments such
as intravitreal anti-angiogenics, which might have encouraged
a larger proportion of individuals with AMD to participate.
Although the prevalence of AMD observed in our study was
similar to that found in other populations, estimates for the
overall prevalence of ARM (10.3% for grades 1e3) appear to
be markedly lower than that might be expected based on
previous studies. To facilitate comparison, table 7 compares the
prevalences obtained for each grade in our study with those
reported in the EUREYE12 and INDEYE26 studies, which used
similar classifications. This comparison shows that the greatest
differences lie in the prevalence of grades 1 and 2 ARM (and
consequently grade 0). The reasons for these differences are not
immediately apparent and merit further investigation. However,
our observation that the prevalence of AMD was similar in our
sample to that reported for other populations may suggest that
earlier grades of ARM are not always accurate indicators of
progression to AMD, as has been suggested previously.27 It
should also be noted that, in our study, grading was initially
performed in each participating centre, as this may have resulted
in differences compared with studies in which all images were
centrally graded.
For individuals with AMD, 69% had severe (Snellen equivalent
20/200e20/400) or very severe (<20/400) deterioration in visual
acuity. This figure is lower than that reported in the population-
based Blue Mountains Eye Study, in which ARM degeneration
was cited as the cause of severe or very severe deterioration in
visual acuity in 21/44 (87.5%).28 Interestingly, in our study, the
effect of ARM/AMD on visual acuity could not be explained by
the presence of cataracts, since the proportion of individuals
with ARM/AMD and reduced visual acuity was similar or lower
in individuals with cataracts compared with those who had
undergone cataract surgery.
In conclusion, this is the first epidemiological study of the
prevalence of ARM and AMD in Spain using a multicentre
design with standardised methodology. The prevalences
observed for AMD were similar to those obtained for a variety of
other populations, although considerably higher than the prev-
alence reported for the Spanish centre included in the EUREYE
study,12 the only other population-based study of ARM and
AMD to include Spanish participants. By contrast, the preva-
lence of ARM was considerably lower than reported for other
populations. Future studies should explore the progression of
ARM to AMD in the Spanish population and analyse possible
regional differences in the prevalence of AMD.
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Molina (Clinic Hospital, Barcelona); Anna Monés (Bellvitge University Hospital,
Barcelona); Javier Montero (Valencia General Hospital); Elisa Nadal (Valme University
Hospital, Seville); Marta Navarro (Valme University Hospital, Seville); Jesus Vicente
Ortiz (La Paz University Hospital, Madrid); Santiago Ortiz (Clinic Hospital, Barcelona);
Iker Otxoa (Bellvitge University Hospital, Barcelona); Ernesto Pereira (Valme University
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